1,2Д«ACKGROUND The presence of IgM antibodies allows for the identification of recent infection and evaluation of disease course.

The AdviseDx SARS-CoV-2 IgG II assay should not be used to diagnose or exclude acute SARS-CoV-2 infection.Дownload SARS-CoV-2 IgG II Semi-Quant EUA ResourcesДЇact Sheet for Recipients:В Understanding the Abbott SARS-CoV-2 IgG II (Semi-Quant) EUA Assay ResultsДЇact Sheet for Healthcare Providers:В Interpreting Abbott SARS-CoV-2 IgG II (Semi-Quant) EUA Assay ResultsДЄnalytical specificity:В No cross-reactivity observed fromВ individuals with other medical conditions, includingВ Human Coronavirus 229E, HKU1, NL63, or OC43. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. The AdviseDx SARS-CoV-2 IgG II assay is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. The AdviseDx SARS-CoV-2 IgG II assay is a chemiluminescent microparticle immunoassay (CMIA) intended for the qualitative and semi-quantitative detection of IgG antibodies to SARS-CoV-2 in human serum (including collected using a serum separator tube) and plasma (acid citrate dextrose, sodium citrate, dipotassium EDTA, tripotassium EDTA, lithium heparin, lithium heparin in a separator tube, and sodium heparin) on the ARCHITECT and Alinity i system.

Sars cov 2 semi quant total ab